NCT04197960

Microwave Ablation and Surgical Resection for Micropapillary Thyroid Carcinoma

Completed NA Last updated 5 August 2025

What this trial tests

NA trial testing Microwave ablation in Papillary Thyroid Carcinoma in 973 participants. Completed in 31 December 2022.

Timeline

1 December 2019

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Chinese PLA General Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	973
Start date	1 December 2019
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across China

Drugs / interventions tested

• Microwave ablation
• Surgical resection

Conditions studied

• Papillary Thyroid Carcinoma — all drugs for Papillary Thyroid Carcinoma →

Sponsor

Chinese PLA General Hospital

Who can join

Adults 18 to 75, any sex, with Papillary Thyroid Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aimed to compare the efficacy and safety of papillary thyroid microcarcinoma (PTMC) treated with microwave ablation(MWA) and surgery resection (SR), and to explore the tumor characteristics suitable for each treatment methods (such as with and without capsular invasion). The investigators organized 18 hospitals to participate in this multicenter study. Patients meeting following indications will be included in this study: 1. Biopsy pathology proved PTMC, but not high-risk subtype; 2. solitary mPTC, without US-detected gross extrathyroid extension; 3. no evidence of metastasis; 4 willing to participate in this study and perform regular follow-up. Patients themselves decide to receive MWA or SR for mPTC after medical consultation. Baseline characteristic including age, gender, thyroid function et al. will be collected. The treatment protocols of MWA and SR were according to the Chinese and international guidelines. The primary outcomes were the disease progression, including local tumor recurrence, lymph node metastasis, and distant metastasis. The secondary outcomes include thyroid function, complication rate, blood loss et al. Investigators will follow up enrolled patients and collect and upload data according to the trial. Treatment outcomes of tumor with and without US-detected capsular invasion was analyzes as subgroups.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

1. Microwave Ablation for Papillary Thyroid Microcarcinoma with and without US-detected Capsule Invasion: A Multicenter Prospective Cohort Study.
   Zheng L, Dou JP, Han ZY, Liu FY, et al · · 2023 · cited 32× · PMID 36880949 · DOI 10.1148/radiol.220661
2. Active Surveillance as an Effective Management Option for Low-Risk Papillary Thyroid Microcarcinoma.
   Jeon MJ, Kim WG, Kim TY, Shong YK, et al · · 2021 · cited 7× · PMID 34379969 · DOI 10.3803/enm.2021.1042
3. Microwave ablation for T1N0M0 papillary thyroid carcinoma located in the isthmus: a multicenter prospective cohort study with over 5-year follow-up.
   Zheng L, Du QW, Dou JP, Liu FY, et al · · 2026 · PMID 42064641 · DOI 10.1177/17588359261442628
4. Microwave Ablation Versus Thyroid Lobectomy for Solitary cT1aN0M0 Papillary Thyroid Carcinoma: A Prospective Multicenter Cohort Study.
   Dou J, Zheng L, Han Z, Che Y, et al · · 2026 · PMID 41800228 · DOI 10.1016/j.mayocpiqo.2026.100696